Spondyloarthritis & psoriatic arthritis
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
Authors' conclusion
Risankizumab was well tolerated and improved symptoms of PsA in Bio-IR/csDMARD-IR patients, with a consistent long-term safety profile from weeks 24 to 52.
Study context
- Population
- Patients with active PsA and previous inadequate response/intolerance to one or two biologics (Bio-IR) or ≥1 csDMARD (csDMARD-IR)
- Participants
- 224 vs 220
- Comparison
- Risankizumab 150 mg SC vs placebo
- Risankizumabn = 224
- Placebon = 220reference
- Primary endpoint
- ACR20
- Follow-up
- Week 24
Methodological detailsphase 3, ongoing, placebo-controlled, follow-up analysis to week 52
- Phase 3
- Ongoing
- Placebo-controlled
- Follow-up analysis to week 52
Primary result
As reported in the abstract
P < 0.001
Further findings
ACR20 · week 52
- ACR20: Placebo group switched to risankizumab at week 24
Other efficacy measures
- Similar trends were observed
Deaths · through week 52
- No deaths reported
Safety
Serious treatment-emergent adverse events (TEAEs) and TEAEs leading to discontinuation · through week 52
- Rates remained stable
Original publication
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford). Published 25 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →